fashion -WSS

fashion

author：Wikipedia 2025-09-30 23:45:31 - browse：3642

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ionis has late

hotspot

WSS

Kaiser Permanente unions announce official strike date

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Dems pitch expanding Medicare power to negotiate drug prices

Will the FTC rein in IQVIA's health data empire?

Why patients can’t get everything they want on drug pricing

Health tech startups drop sharply from 2021 highs

leisure time

fashion

hotspot

Apple is now the first public company to be valued at $3 trillion

Ionis has late

Malaria cases in Florida and Texas: Here’s what you need to know

How doctors’ personal politics affect patients

Apple is now the first public company to be valued at $3 trillion

Data show record exodus of life scientists from academia

Walensky prepares to leave CDC — and Congress — behind

Biogen shutters digital health group, ends Apple study, in cost cutting move

Peter Hotez and the public health issue of online harassment

What causes rare myocarditis in young men after Covid vaccines?

entertainment

FDA advisers vote against ALS treatment from BrainStorm

Why patients can’t get everything they want on drug pricing

Why patients can’t get everything they want on drug pricing

What it's like to live with paralysis for one psychologist

Would Medicare drug price negotiations stall in a shutdown?

Senate panel puts off hardest PBM reforms for another day

hotspot

hotspot

hotspot

hotspot